Synchronous development of KIT positive acute myeloid leukemia in a patient with gastrointestinal stromal tumor by Joo, Young-Bin et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
VOLUME 45ㆍ NUMBER 1ㆍ MARCH 2010
THE KOREAN JOURNAL OF HEMATOLOGY CASE REPORT
Synchronous development of KIT positive acute myeloid leukemia 
in a patient with gastrointestinal stromal tumor
Young-Bin Joo
1, Seung Hwa Choi
1, Seung Kyoung Kim
1, Byungyong-Shim
1, Myung-Shin Kim
2, 
Yoo-Jin Kim
3
1Department of Internal Medicine, St. Vincent Hospital, Departments of  
2Diagnostic Laboratory, 
3Internal Medicine, Seoul St. Mary’s
Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea 
p-ISSN 1738-7949 / e-ISSN 2092-9129
DOI: 10.5045/kjh.2010.45.1.66
Korean J Hematol 2010;45:66-9.
Received on February 20, 2010
Revised on March 9, 2010
Accepted on March 9, 2010
We report a case of synchronous occurrence of KIT-positive acute myeloid leukemia 
(AML) and gastrointestinal stromal tumor (GIST). A 63-year-old woman was hospitalized 
for dizziness, and abdominal computed tomography revealed an exophytic gastric mass 
and hepatic metastasis. The patient was diagnosed with GIST and was administered im-
atinib (400 mg/day) for the metastatic unresectable tumor. After 2 weeks of imatinib treat-
ment, the patient developed pancytopenia, which persisted even after the drug was dis-
continued, thereby necessitating bone marrow biopsy. Biopsy examination indicated 
AML, and karyotyping revealed a complex karyotype. We did not observe point mutations 
at residues D816 and N822 of KIT. Therefore, the patient received standard induction che-
motherapy, but on the 18
th day after completion of chemotherapy, she died of septic shock 
and multi-organ failure. Since KIT plays an important role in both GIST and AML, we con-
sider that both these malignancies may have been associated with each other. 
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INTRODUCTION
  Gastrointestinal stromal tumors (GISTs) are the most com-
mon mesenchymal tumors of the gastrointestinal tract. Most 
of the GISTs occur in the stomach (60%), jejunum and ileum 
(30%), and the duodenum (5%). GISTs comprise a biological 
spectrum of small benign nodules to fully malignant sarcomas 
[1]. The development of GIST is associated with the muta-
tional activation of receptor tyrosine kinases, namely, the 
platelet-derived growth factor receptor-a (PDGFRA) or KIT 
[1-3].
  KIT is a type III receptor protein tyrosine kinase that 
is involved in the development and maintenance of eryth-
ropoietic stem cells, mast cells, melanocytes, germ cells, and 
interstitial cells of Cajal [4]. Over-expression and/or con-
stitutive expression of KIT alone or in conjunction with 
a stem cell factor (SCF) induces several solid tumors, includ-
ing small-cell lung carcinoma, neuroblastoma, pancreatic tu-
mors, and several hematological malignancies [5]. Moreover, 
mutations involving the KIT exons 8 and 17 and to a less 
extent, the KIT exons 9 and 11 have been identified in 
these malignancies. 
  Previous studies have shown an association between GIST 
and other malignancies such as hepatocellular carcinoma, 
adenocarcinoma, mastocytosis, and lymphoma/leukemia [6- 
11], but synchronous occurrence of GIST and leukemia has 
not been reported. Here, we report the first case of synchro-
nous development of KIT-positive acute myeloid leukemia 
(AML) and GIST. The potential nonrandom association and 
causal relationship between GIST and AML need to be 
investigated.
CASE REPORT
  A 63-year-old woman was hospitalized after experiencing 
dizziness and fatigue for 2 months. Her physical examination 
was unremarkable, with the exception of pale conjunctivae. 
The initial laboratory tests revealed a white cell count of 
3.08×10
9/L, a hemoglobin level of 6.3 g/dL, and a platelet 
count of 80×10
9/L. Endoscopy revealed an ulcerofungating 
mass lesion of about 6.0×6.0 cm in the posterior wall of Korean J Hematol 2010;45:66-9.
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Fig. 1. Esophagogastroenteroscopy shows an ulcerofungating mass 
lesion in the posterior wall of the gastric fundus. The mass is covered 
with normal mucosa-like submucosal tumor, but it has a large ulcera-
tion at the centre.
Fig. 2. Abdominal computed tomography shows an 8×7.3 cm 
exophytic gastric mass in the posterior wall of the gastric body 
containing a large area of cavitation and variable hepatic metastasis.
Fig. 3. (A) Poorly differentiated mali-
gnant-cell infiltrates with epithelioid
features in the myxoid stroma. (B)
Immunohistochemical staining of 
cytokeratins (CK MNF116) is ne-
gative.  (C) Immunohistochemical 
staining of KIT is positive. (D) The 
uniform population of primitive my-
eloblasts is indicative of acute my-
eloid leukemia.
the high body-fundus (Fig. 1). Abdominal computed tomog-
raphy revealed an exophytic gastric mass and hepatic meta-
stasis (Fig. 2). The histopathologic analysis showed poorly 
differentiated malignant-cell infiltrates with epithelioid fea-
tures in the myxoid stroma. Immunochemical staining of 
these cells was positive for CD117 and CD 34, thereby indicat-
ing GIST (Fig. 3A-C). However, KIT tyrosine kinase mutation 
in the gastric samples was not examined. The patient initially 
received imatinib mesylate (400 mg/day) to treat the meta-Korean J Hematol 2010;45:66-9.
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static unresectable tumor.
  On the 14th day of imatinib treatment, complete blood 
cell count showed a white cell count of 1.87×10
9/L, hemoglo-
bin level of 8.7 g/dL, and a platelet count of 29×10
9/L. 
Pancytopenia persisted even after discontinuation of im-
atinib, and bone marrow biopsy revealed a markedly hyper-
cellular marrow with infiltrates of myeloblasts (26%), there-
by indicating AML with maturation (Fig. 3D). The karyotyp-
ing showed 39-47,XX,add(4)(q12),der(5;22)(p10;q10),+der 
(5;22),add(12)(p11.2),-17,-19,-20,+1-2marcp [19]/46, XX [1]. 
Immunophenotyping was positive for CD117, CD33, CD34, 
CD38, CD56, and CD7. We did not observe point mutations 
at residues D816 and N822 of KIT. Therefore, the patient 
underwent chemotherapy with idarubicin (12 mg/m
2
/day) 
for 3 days and cytarabine (200 mg/m
2/day) for 7 days, but 
on the 18
th day after the completion of chemotherapy, she 
died of septic shock and multi-organ failure.
DISCUSSION
  T h e  d e v e l o p m e n t  o f  G I S T  i s  b e l i e v e d  t o  b e  a s s o c i a t e d  
with the mutational activation of receptor tyrosine kinases, 
namely, KIT or PDGFRA [1]. Up to 75% of the activating 
KIT mutations that usually affect the juxtamembrane domain 
(exon 11) induce ligand-independent phosphorylation. A 
small number of GISTs, especially those of the gastric cells 
with epithelioid morphology, show PDGFRA mutations, 
which are mostly observed in the tyrosine kinase domain 
(exon 18) [1-3].
  KIT is also an important pathogenetic factor in AML. 
KIT expression is significantly higher in AML blasts than 
in normal bone marrow cells, and one-third of the AML 
blasts co-express KIT and SCF, thereby suggesting autocrine 
and paracrine stimulation of KIT by SCF [5]. Moreover, 
KIT mutation involving exon 8 was observed in 20% of 
the patients with inv(16); KIT mutation involving exon 17 
was expressed in a patient with t(8;21).
  Since KIT plays a role in both GIST and AML, these malig-
nancies may be associated. In 1997, a case of leukemia was 
reported, in which the disease developed after jejunal GIST 
[12]. The jejunal GIST was treated surgically, and the patient 
underwent chemotherapy with fluorouracil; however, a 
month later, the patient was diagnosed with acute promyelo-
cytic leukemia. Leukemia was considered as the second ma-
lignancy, which developed after chemotherapy for GIST. 
However, in our case, GIST and AML were diagnosed syn-
chronously. To the best of our knowledge, this is the first 
case report in which KIT-positive AML and GIST were syn-
chronously observed. The results of an epidemiologic analysis 
indicated a nonrandom association between AML and GIST 
[9, 10]. Agaimy et al. [9] reported that lymphoma/leukemia 
developed in 7% of GIST patients. Miettinen et al. [10] exam-
ined the long-term follow-up data of 1892 GIST patients; 
among these, 6 patients had AML and 3 had chronic myeloid 
leukemia. In these patients, the leukemia developed 1.7-21 
years after the GIST (median interval, 6 years). Moreover, 
the risk of AML was found to be significantly higher for 
women, as observed in our case.
  The common pathogenesis of KIT activation or mutation 
in GIST and AML has still not been elucidated. However, 
the fact that KIT tyrosine kinase activation or mutation plays 
an important role in both GIST and AML corroborates that 
the 2 tumors are associated and do not develop incidentally 
as independent tumors. The possible causes for their associa-
tion are as follows. First, the activated KIT pathway is in-
volved in leukemogenesis in GIST patients. The hema-
topoietic progenitor cells are dependent on the KIT-signaling 
pathway. The KIT mutation in AML is structurally and func-
tionally similar to that in GIST. For example, the KIT muta-
tions involving exon 8 and the internal tandem duplications 
involving KIT exon 11 occur in both AML and GIST. Second, 
the circulating KIT ligand, SCF, which is detected in GIST 
patients, has a humoral effect on bone marrow precursors; 
this probably leads to myeloproliferation and ultimately to 
the development of leukemia.
  Here, we report a case of synchronous occurrence of 
KIT-positive AML and GIST. These 2 tumors are considered 
to be nonrandomly associated rather than being double pri-
mary tumors. For appropriate treatment of these 2 malig-
nancies, further investigations such as molecular therapeutic 
targeting of KIT signaling pathway and its impact on the 
response to tyrosine kinase inhibitors, are required.
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